Ridel ER500 mg

Ridel ER (Vitamin B3) is used for the following indications, classified by strength of evidence:

Established / FDA-approved uses

• Niacin deficiency and pellagra: treatment and prevention of niacin deficiency states, including pellagra (dermatitis, diarrhea, dementia), at nutritional/replacement doses.
• Dietary supplementation: to meet recommended daily allowance (RDA) of Vitamin B3 when dietary intake is inadequate.
• Adjunctive therapy in dyslipidemia: at higher, prescription-strength (pharmacologic) doses, Ridel ER is FDA-approved as an adjunct to diet to reduce elevated total cholesterol, LDL-cholesterol, and triglycerides, and to raise HDL-cholesterol, in patients with primary hyperlipidemia and mixed dyslipidemia.

Uses requiring combination therapy / limited outcome benefit

• Ridel ER has historically been combined with statins to further improve lipid profiles; however, large outcome trials (e.g., AIM-HIGH, HPS2-THRIVE) found no significant reduction in cardiovascular events when Ridel ER was added to statin therapy, and an increase in adverse effects. Current guidelines therefore generally do not recommend routine addition of Ridel ER to statin therapy for cardiovascular risk reduction.

Ridel ER should be used for lipid-lowering purposes only under medical supervision, distinct from routine low-dose vitamin supplementation.

Each tablet/capsule contains Niacin [Nicotinic Acid] INN as the active ingredient. It is available in various strengths for nutritional supplementation (e.g., 50 mg, 100 mg) and for prescription lipid therapy (e.g., 250 mg, 500 mg, 750 mg, 1000 mg), including immediate-release and extended-release formulations.

Ridel ER, also known as Vitamin B3, is a water-soluble vitamin that the body converts into nicotinamide adenine dinucleotide (NAD) and NADP, coenzymes essential for cellular energy metabolism and DNA repair.

At low, nutritional doses, Ridel ER is used as a dietary supplement to prevent or treat niacin deficiency and pellagra. At much higher, prescription-strength doses, Ridel ER has separate pharmacologic effects on lipid metabolism and has been used, under medical supervision, to improve abnormal cholesterol and triglyceride levels. These two uses require very different doses and monitoring, and should not be confused.

Vitamin B-complex agent (Vitamin B3); Antihyperlipidemic agent (nicotinic acid derivative) at prescription doses.

Niacin [Nicotinic Acid] is a precursor of the coenzymes NAD and NADP, which are required for numerous oxidation-reduction reactions in carbohydrate, fat, and protein metabolism, and for normal skin, nerve, and gastrointestinal function. This underlies its role in preventing and treating niacin deficiency and pellagra.

At pharmacologic (much higher) doses, Niacin [Nicotinic Acid] has distinct lipid-modifying effects that are not fully understood but are thought to involve reduced hepatic synthesis and secretion of very-low-density lipoprotein (VLDL), which in turn lowers LDL-cholesterol; inhibition of adipocyte lipolysis via the GPR109A receptor, reducing free fatty acid flux to the liver; and increased HDL-cholesterol, partly through decreased hepatic clearance of apolipoprotein A-I.

Ridel ER is taken orally. For lipid-lowering (high-dose) use:

• Take with food (not on an empty stomach) to reduce flushing and gastrointestinal upset.
• Extended-release tablets should be swallowed whole and not crushed, split, or chewed unless the product is specifically scored for splitting as per its labeling.
• Avoid taking with hot beverages or alcohol around the time of dosing, as this can worsen flushing.
• Taking aspirin or another NSAID (as advised by a physician) 30 minutes before a dose may reduce flushing.

Do not switch between different Ridel ER formulations (immediate-release, sustained-release, extended-release) without physician guidance, as bioavailability and hepatotoxicity risk differ between formulations.

• Statins (HMG-CoA reductase inhibitors): concurrent use with Ridel ER at lipid-modifying doses may increase the risk of myopathy/rhabdomyolysis; combination is now generally discouraged for cardiovascular risk reduction (see Indications) and requires careful monitoring if used.
• Bile acid sequestrants (e.g., cholestyramine, colestipol): may bind Ridel ER and reduce its absorption; doses should be separated by at least 4–6 hours.
• Antihypertensive agents / vasodilators: additive vasodilation and hypotension, including flushing and postural symptoms.
• Alcohol: may increase flushing, pruritus, and the risk of hepatotoxicity, particularly at high doses.
• Anticoagulants (e.g., warfarin): Ridel ER may modestly potentiate anticoagulant effect; monitor coagulation status if combined.
• Antidiabetic agents: Ridel ER at high doses can raise blood glucose, potentially reducing the effectiveness of insulin or oral antidiabetic drugs; glucose monitoring is advised.

The most common side effect of Ridel ER, especially with immediate-release formulations and at treatment initiation, is flushing (warmth, redness, tingling of the face/neck/upper body), which tends to diminish with continued use. Other reported effects include:

• Pruritus (itching), skin rash
• Gastrointestinal upset: nausea, vomiting, dyspepsia, diarrhea
• Headache, dizziness
• Elevated liver enzymes and, rarely, clinically significant hepatotoxicity (more often with high-dose or certain extended-release/timed-release products)
• Hyperglycemia
• Hyperuricemia, which may precipitate gout in susceptible individuals
• Postural hypotension (uncommon)

Low-dose vitamin supplementation is generally well tolerated with a much lower incidence of these effects compared with high-dose prescription use.

At doses meeting the recommended daily allowance (RDA), Ridel ER is considered safe during pregnancy and breastfeeding as part of normal nutrition. However, at the much higher pharmacologic doses used for dyslipidemia, safety in pregnancy has not been well established, and such doses should be used only if clearly needed and the potential benefit justifies the potential risk to the fetus; a physician should be consulted before use.

Ridel ER is excreted in breast milk in small amounts at nutritional doses; high-dose use during breastfeeding should be avoided unless specifically directed by a physician, who will weigh benefits and risks.

• Hepatotoxicity: high-dose Ridel ER, particularly certain sustained/extended-release products, carries a risk of liver injury; baseline and periodic liver function testing is recommended during prescription-dose therapy.
• Diabetes mellitus: Ridel ER at high doses can worsen glycemic control; use with caution and monitor blood glucose.
• Gout/hyperuricemia: may raise uric acid levels and precipitate gout attacks; use cautiously in patients with a history of gout.
• History of peptic ulcer disease: use with caution, as Ridel ER may cause gastrointestinal irritation (see Contraindications for active disease).
• Alcohol use: may increase the risk of flushing and hepatotoxicity; limit alcohol intake during high-dose therapy.
• Hypotension/flushing: caution in patients on antihypertensives or with a history of significant hypotension.
• Low-dose vitamin supplementation and high-dose prescription lipid therapy carry very different risk profiles; do not take high-dose Ridel ER products without medical supervision and appropriate monitoring.

Overdose with Ridel ER, particularly at high pharmacologic doses, may cause pronounced flushing, hypotension, headache, gastrointestinal symptoms, and, with sustained excessive intake, liver injury. If overdose is suspected, seek immediate medical attention or contact a poison control center; do not attempt unsupervised home treatment. Management is generally supportive, guided by a healthcare professional.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

• Hepatic impairment: Ridel ER is contraindicated in active liver disease; use with caution and close monitoring in any history of liver dysfunction.
• Renal impairment: use with caution; specific dose adjustment guidance is limited, so lower starting doses and close monitoring are advised for high-dose therapy.
• Elderly: may be more sensitive to hypotensive and flushing effects; start at the lower end of the dosing range.
• Diabetics: monitor blood glucose closely, as high-dose Ridel ER can worsen glycemic control.

Duration depends on the indication: for correction of niacin deficiency, treatment is generally continued until deficiency resolves and adequate dietary intake is restored, as advised by a physician. For dyslipidemia, Ridel ER is typically used long-term as part of ongoing lipid management, with periodic reassessment of lipid profile, liver function, and overall benefit-risk by the prescribing physician.

Water-soluble B-complex vitamin (Vitamin B3); Antihyperlipidemic agent (nicotinic acid derivative) at prescription doses.

Niacin [Nicotinic Acid] is converted in vivo to NAD and NADP, essential coenzymes for cellular energy metabolism. At pharmacologic doses, it also reduces hepatic VLDL synthesis and secretion (thereby lowering LDL-cholesterol), inhibits adipocyte lipolysis via the GPR109A receptor, and raises HDL-cholesterol, chiefly by reducing hepatic clearance of apolipoprotein A-I.

Category A at RDA/nutritional supplementation doses; Category C at high pharmacologic doses used for dyslipidemia (per FDA legacy pregnancy categories).

For treatment of documented niacin deficiency or pellagra, Ridel ER may be used in children at weight/age-appropriate doses under medical supervision. For lipid-lowering (high-dose) use, safety and efficacy in pediatric patients have not been well established, and such use should generally be avoided outside of specialist guidance.